Research aims to provide physicians more targeted approach to treating ER+ breast can

[schoonder]

Driving force behind I-SPY2 trial is to reduce size of phaseIII trials in order to get new, effective drugs approved for early BC indications in most expedient fashion.
http://www.clinicaltrials.gov/ct2/sh...2+t-dm1&rank=1